The questions boards ask before they sign.

Enterprises with five hundred to two thousand five hundred employees. Below that band the fixed tariff does not amortise; above it the delivery model loses the directness that makes it work.

Within the organisation, the programme addresses the C-level board: chief executives, chief financial officers, chief operating officers and board directors, together with top sales agents where an introduction is being made.

Because they are rarely party to a decision of this size, and because the register of the room changes when the conversation moves from financial exposure to benefits administration.

This is not a comment on the function. Human resources becomes central the moment deployment begins — but the commercial case is made to the people who carry the number on the balance sheet.

There is no waiting list, because there is no second cohort. Submit the enquiry with your headcount noted and the office will respond with what is possible — but the ninety-nine companies are reserved for enterprises inside the band.

A single recurring enterprise tariff of £150,000, billed quarterly — £600,000 across a full contract year.

There is no tiered menu, no discovery fee and no per-seat escalator. The tariff covers the executive board and every employee in the organisation.

The tariff is set and contracted in Pound Sterling, because the service is provided predominantly to United Kingdom and United States enterprises.

Clients invoiced outside the United Kingdom have local-currency billing applied on the invoice at the prevailing rate — United States Dollars in the US, Euro in the euro area, Singapore Dollars in Singapore, and so on.

Yes. A compliant invoice is generated and issued to every client automatically, the moment payment settles. No manual request is required and no invoice is raised by hand.

The quarterly tariff is settled by bank transfer — Faster Payments or CHAPS in the United Kingdom, SEPA credit transfer in the euro area, wire or ACH in the United States. A secure payment link is issued with each invoice, and clients settling in US dollars may place the quarterly instalments on an ACH direct debit mandate so that nothing needs re-authorising each quarter.

Clients who prefer the quarterly payment to run without anyone re-approving it may place a standing order with their own bank against the account details issued with the invoice. It repeats automatically, it is matched to each invoice on arrival, and because the payment is sent by you rather than collected by us it can never be reversed against your account. We do not operate direct debit mandates in the United Kingdom or the euro area for this reason.

Payment is accepted only from a business account in the name of the contracting organisation.

Corporate cards are not used at this value. Company card limits rarely accommodate a six-figure single charge, and the card processing fee on a £150,000 instalment is a cost we decline to pass on to the client.

For a first payment at this value, the office will confirm the settlement route with your finance team in advance so that funds clear without an intermediate review hold.

Each invoice states its due date, and reminders are issued automatically before and after it. Where an invoice passes its due date, interest accrues from that date at the statutory rate for commercial debts, together with the fixed compensation provided by law.

Where an invoice is still unpaid thirty days after the due date, delivery may be suspended on written notice — the annual employee broadcast and its link, the biannual testing of the executive board, and the seat at the annual executive summit — until the balance is settled. The twelve-month term is not paused or extended by a suspension, and the quarterly tariff continues to accrue.

Two things are never affected. Individual results already released through the laboratory’s portal are not withheld, and no clinically urgent finding is ever delayed by a billing matter. A commercial dispute does not reach anyone’s health.

Quarterly billing aligns the contract to the board’s own reporting cycle, so the cost lands in the same rhythm as the internal reporting that tracks the recovery. It also removes the administrative friction of a monthly renewal at this value.

It renews automatically. The engagement runs on a twelve-month term. Unless notice is given under the engagement contract, the term rolls into another twelve months and the quarterly tariff continues on the same basis, and so on — the relationship is built to be a long one, not a course that finishes.

Renewal keeps your seat at the annual executive summit. Participation in the yearly executive summit — the networking room where the ninety-nine convene — is exclusive to clients whose engagement is unbroken. A client that ends the engagement and is later re-admitted pays an additional £30,000 per quarter on re-entry.

The digital concierge service is non-refundable. Once access has been made available the fee is not refunded in whole or in part, including where a session is not attended or the engagement is ended mid-term, because the service is supplied digitally and in full from the moment access is granted. The full wording is in the terms of engagement.

The measured history, and the room. The executive baseline is set at the first biological optimisation test and every six-month retest is read against it. That accumulated baseline — and the cohort benchmarking built on it — attaches to the engagement and cannot be reconstructed elsewhere. An organisation that leaves starts again from zero.

Access ends with the engagement: the annual employee broadcast link stops working for the workforce from the day the engagement ends, and the seat at the annual executive summit is released. Re-admission, where offered, carries an additional £30,000 per quarter — so the economical route is an unbroken term.

Ninety-nine companies in total, plus Mathias Koester as host. The founding cohort convenes on Friday 30 October 2026 at 13:00 UTC — 09:00 New York, 13:00 London, 21:00 Bali.

One seat is one enterprise, not one person. The seat is held by the company. Your attending directors are named to the office on reservation and may be changed by written notice — the Zoom session and the in-person meeting are for the executive board only.

The cap is hard, and it is permanent. This is the only cohort — when the seats are gone the programme closes to new clients and no further cohort is opened. Everything after that point is given to the ninety-nine already inside it.

No. The biological optimisation test for the C-level board is free of charge and included in the tariff. No separate diagnostic invoice is raised.

It is taken every six months — the first test sets the executive baseline and each retest measures the movement against it. Both are covered by the same tariff.

Every employee in the organisation receives a dedicated online session once a year, included in the tariff at no additional cost. It is delivered as a pre-recorded broadcast, so the same message reaches the entire workforce at once and no live connection can fail mid-session.

How your employees receive it. A single access link is issued to one named responsible person inside your organisation, who circulates it to the workforce by internal email. Nothing is required of your IT department, no employee account is created, and Four Diamond Wellness never holds your employee list.

The link is a plain URL, so the responsible person may equally place it on the company intranet or in the learning-management system — it embeds anywhere a link can live, with no integration project and no involvement from IT.

It sets out the facts of the deficiencies that are costing the business and what each person should do about them. The C-level board is handled separately — live on Zoom, followed by the in-person meeting at a top-tier hotel.

This is not an afterthought. Company-wide presenteeism and medical cost is where the volume of the financial saving actually sits — the executive tier is where the decision quality sits.

Mathias Koester, personally, to the founding cohort. The work is not delegated to an account team, white-labelled or subcontracted.

Each executive sees their own result. Their employer never does. The full panel is delivered to the individual personally, through the laboratory’s accredited secure results portal. It is read by the practitioner responsible for that executive’s protocol, under clinical confidentiality, because scoring and adjustment require it. Beyond that it goes nowhere: it is never uploaded to this website, and it is never shown to the employer — not on request, and not for the chief executive asking about his own directors.

The board receives an aggregated cohort report instead: percentages, never people, with no group smaller than ten ever described. The in-person meeting and the Zoom session work from that report alone — nobody’s numbers are ever on the screen. Anything clinically urgent is escalated the same day, to the individual personally, with a referral to their own physician.

The full architecture is set out on Your Results.

Every engagement is governed by a strict non-disclosure agreement. No client logo appears on this site and none ever will.

Outcomes are published in anonymised form, with sector and scale indicated so the result remains interpretable, and the client never identified.

The evidence vault opens with a codeword issued by your Four Diamond representative alongside your invitation. It contains the baseline model, corporate financial modelling at two hundred, three hundred and five hundred employees, replacement economics, executive-tier returns, the biomarker evidence and every source document as a downloadable PDF.

Request access from the office if you have not yet been issued a code.

No, and any provider claiming otherwise should be treated with suspicion. The figures published across this site are modelled estimates drawn from peer-reviewed health-economics literature and from client engagements.

Outcomes vary by sector, headcount, baseline severity and adoption. What the programme does guarantee is that the measurement framework is built in from the first quarter, so the result is auditable against the tariff rather than asserted.